Does this help? Taken from post 1598, bottom of page
Competition:
The competition mainly uses outdated blood. They try and clean it up, cross link it, etc. to create artificial blood. Another problem is that there is not enough outdated blood in the world to produce enough for 60 million transfusions let alone 120-180 million transfusions/per year.
Dr. Drees, author and noted expert, who lectures 2-3 times a year in the field, had prophesied from the beginning that the competitors would have problems. And problems they have had. There were about a dozen companies in blood substitutes about 10 years ago. Here's what is going on with some of the few survivors.
1. Baxter: In a 100 person trial, 40 people died (in the U.S.A.). European trials have also been stopped.
2. Alliance: Used fluorocarbons like Sanguine does but a different form. Had strategic alliance with Johnson & Johnson and the German company Hoescht. Both companies canceled their funding.
3. Somatogen: Uses recombinant DNA. Had agreement with Eli Lilly. Eli Lilly canceled agreement. Baxter has recently acquired Somatogen.
4. Biopure: Had contract with Upjohn. Upjohn canceled contract. Biopure uses cow's blood.
The good thing is that the competition has had numerous troubles. The bad thing is that this gives the product line a negative image. Remember that Sanguine's technology is different from the competitors. Sanguine's technology does not use outdated blood, cow's blood,etc. Also, Sanguine's technology is second generation, i.e. there was a successful 1st generation, but it was dropped by Japanese drug company, Green Cross Corp., due to false dates. Green Cross Corp. had no patents, so Sanguine patent application is effective.
Sanguine and Dr. Drees phone number: 626-405-0079
Bob |
